Media Center
Press Releases
25 Sep 17

Back to posts

Successor to PD-1 inhibitors the focus of cancer immunotherapy development, says GBI Research

 The cancer immunotherapies pipeline, which comprises of 3,100 products and encompasses over a third of all products in development for oncology, displays a high level of first-in-class innovation with novel developments focusing heavily on producing the next big immune checkpoint inhibitor, according to business intelligence provider GBI Research.


The company’s latest report: ‘Cancer Immunotherapies – First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets’ states that over 75% of the most promising cancer immunotherapy drug targets are classified as immune checkpoint proteins, indicating massive potential for cancer immunotherapies that directly modulate the immune system.

Emily Leckenby, Analyst for GBI Research, explains: ''As knowledge of the anti-cancer immune response increases, advances in the development of immunotherapies has followed. Both commercial and therapeutic success of immune checkpoint inhibitors Opdivo and Keytruda has driven an influx of pipeline programs focusing on targeting immune system function rather than cancer cells directly. Targeting of the immune system has potential for use across oncology indications, attributing to its commercial success as a therapy strategy.''

Additionally, the cancer immunotherapies pipeline displays a high level of first-in-class innovation, with 989 of 3,100 pipeline programs involving therapeutic targets with no current market interest.

Leckenby adds: ''Many of these previously unexplored targets display a high probability in replicating the success of previous immune checkpoint inhibitors, despite struggles faced in progressing cancer immunotherapies into late stage development.''

According to GBI Research, over 60% of first-in-class programs are at an early stage of development (Discovery and Preclinical) compared to less than 1% that reach late stage development (Phase III and Pre-Registration). Despite this, over $15 billion has been invested into co-development deals involving immune checkpoint protein-targeting products over the last 10 years, an amount almost ten-times larger than those associated with other target types within the pipeline.

Leckenby concludes: ''This high level of investment indicates that immune checkpoint proteins are an extremely valuable therapeutic target commercially, regardless of the risks associated with bringing cancer immunotherapies to market.''

Information based on the GBI Research Report: Cancer Immunotherapies – First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

-ENDS-

NOTES TO EDITORS

 Editor’s notes

- Comments provided by Emily Leckenby, Analyst at GBI Research

The report covers: the most compelling first-in-class innovation within the cancer immunotherapies pipeline, highlighting which specific molecular targets and associated drugs are most likely to be key players in the future market. The report also includes a detailed introduction to cancer, the current market landscape, the pipeline landscape and an analysis of the deals landscape.

ABOUT GBI RESEARCH

GBI Research is a market-leading provider of business intelligence reports,offering actionable data and forecasts based on the insights of key industry leaders to ensure you stayup-to-date with the latest emerging trends in your markets.

For further details, please Contact Us.

Latest Press Releases

Close

Send this to a colleague

I have read and accept terms and conditions and privacy policy

Cancel